Loading...
Loading...
Sucampo Pharmaceuticals
SCMP today announced that the
Japan Science and Technology Agency (JST) has adopted unoprostone
isopropyl ophthalmic solution .15% in the Adaptable and Seamless
Technology Transfer Program. As part of this program, R-Tech Ueno,
Sucampo's development partner, has signed an agreement for unoprostone
isopropyl with the JST in which the Japanese government shall provide
the majority of funding* for Phase 3 clinical development costs for
unoprostone isopropyl for retinitis pigmentosa (RP). Sucampo is
co-developing unoprostone isopropyl with R-Tech Ueno and may file for
FDA approval of the product for retinitis pigmentosa (RP) in the future
assuming the successful trials.
A form of unoprostone isopropyl, trade name RESCULA®, is
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in